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Abstract
Background: Pluri-potent bone marrow stromal cells (MSCs) provide an attractive opportunity to generate unlimited
glucose-responsive insulin-producing cells for the treatment of diabetes. We explored the potential for human MSCs
(hMSCs) to be differentiated into glucose-responsive cells through a non-viral genetic reprogramming approach.
Methods and Findings: Two hMSC lines were transfected with three genes: PDX-1, NeuroD1 and Ngn3 without subsequent
selection, followed by differentiation induction in vitro and transplantation into diabetic mice. Human MSCs expressed
mRNAs of the archetypal stem cell markers: Sox2, Oct4, Nanog and CD34, and the endocrine cell markers: PDX-1, NeuroD1,
Ngn3, and Nkx6.1. Following gene transfection and differentiation induction, hMSCs expressed insulin in vitro, but were not
glucose regulated. After transplantation, hMSCs differentiated further and ,12.5% of the grafted cells expressed insulin. The
graft bearing kidneys contained mRNA of insulin and other key genes required for the functions of beta cells. Mice
transplanted with manipulated hMSCs showed reduced blood glucose levels (from 18.9+/20.75 to 7.63+/21.63 mM). 13 of
the 16 mice became normoglycaemic (6.9+/20.64 mM), despite the failure to detect the expression of SUR1, a K
+-ATP
channel component required for regulation of insulin secretion.
Conclusions: Our data confirm that hMSCs can be induced to express insulin sufficient to reduce blood glucose in a diabetic
mouse model. Our triple gene approach has created cells that seem less glucose responsive in vitro but which become
more efficient after transplantation. The maturation process requires further study, particularly the in vivo factors influencing
the differentiation, in order to scale up for clinical purposes.
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Introduction
Restoring beta cell mass by islet cell transplantation in type 1
diabetes has become a realistic option for the treatment of Type 1
diabetes mellitus (T1DM) [1], although it faces problems,
including a very limited supply of donor organs; the tendency
for loss of islet function in vivo over time; toxicity of current
immunosuppression regimens and risk of rejection and reoccur-
rence of autoimmune attack. In order to make beta cell
replacement a more broadly applicable therapy, a source of
surrogate glucose regulated insulin-secreting cells, preferably
autologous, must be harnessed. Human MSCs, also known as
colony-forming-mesenchymal cells, are readily expanded in vitro
[2,3] and can be derived from bone marrow as well from
peripheral blood [4]. These cells contain long telomeres [5] and no
telomerase activity [6,7]. As both length of telomeres and
telomerase activity are implicated in the immortality of tumour
cells [8–10] and embryonic stem cells [10,11], the lack of
telomerase activity in hMSCs may imply reduced likelihood of
tumour generation. MSCs have been shown to express both
archetypal stem cell markers and early markers of differentiated
tissues [12–15] and also have the potential to differentiate into a
variety of cell types and tissues [16–19], including insulin-
producing cells [5,20–22], albeit at low level. One recent
publication documented the production of insulin expressing cells
sufficient to improve, although not normalise, hyperglycaemia in
diabetic mice through an adeno-rat Pdx-1 recombinant virus [23].
We have used a stepwise, non-viral genetic reprogramming
approach, in order to influence hMSCs to differentiate into cells
with properties of the beta cell phenotype in vitro, in readiness for
subsequent maturation into glucose-responsive insulin-producing
cells in vivo. We have analysed the phenotype of these cells in
comparison with human islet cells.
Methods
Cell Culture
Two human stromal cell lines (220R and 240L) [24], donated
by Professor Darwin J. Prockop, Center for Gene Therapy,
Tulane University, were used in this study. The cells were assigned
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st passage on arrival at King’s. The cells were cultured in a-
MEM (Sigma, Dorset, UK) supplemented with 16.67% FCS at
37uC in a humid 5% CO2 incubator and expanded by culturing at
,2% density (60,000/10 cm petri dish) and harvested at ,30% to
prevent the loss of multipotency. For differentiation induction
study, cells at passage 4–6 were used.
Cell proliferation assay
Cells were seeded at ,2% density and cultured for 5 days.
Portions of the cells were dissociated with trypsin/EDTA solution
daily and cell number was counted. The remaining dissociated
cells were centrifuged down as a pellet, processed for cryosections
and stained for the Ki67 marker as described previously [25].
Human Pdx-1, NeuroD1 and Ngn3 expression plasmids
and transfection
The coding regions of the human PDX-1, NeuroD1 and Ngn3
genes were amplified respectively by RT-PCR using specific primer
sets (Table 1). The genes were then respectively cloned into the
expression plasmid–pIRES-N1 [26] under the control of CMV
promoter and the three genes were partially sequenced. For gene
transfection, the cells were seeded at ,90% confluence for 3 hrs
before transfection with lipofectamine 2000 (Invitrogen, Paisley, UK)
according to manufacturer’s instructions as described previously [25].
The plasmid DNA of Pdx-1, NeuroD1 and Ngn3 were mixed in a
ratio of 1:3:1 in weight prior to the transfection. The triple gene
transfected hMSCs were then termed hMSC/PNNs. Empty
plasmid–pIRES-N1 was used as a negative transfection control.
Differentiation induction
To induce the hMSC/PNNs into a low-degree differentiation in
vitro, the cells were converted into cluster culture in CMRL1066
medium (Invitrogen, Paisley, UK) overnight, 48 hrs after the triple
gene transfection. The following morning, a cocktail of differen-
tiation induction reagents was added to a final concentrations of
25pM activin A, 200pM betacellulin (R&D Systems, Oxford, UK),
10 mM nicotinamide (Sigma, Dorset, UK) and 16.5 mM glucose
(termed ABNG) plus 10% FCS. The medium is replaced every 2
days with fresh ABNG. Cell samples were taken and assessed for
expression of b-cell markers at the end of 6 days culture.
Semi-quantitative RT-PCR
Total RNA was isolated using a RNA Miniprep Kit (Promega,
Southampton, UK) and quantified using a spectrometer (Gene
Quant II, Pharmacia Biotech) at 260 nm wavelength described
previously [25,27]. Briefly, 100 ng total RNA was converted into
the 1
st strand cDNA with reverse transcriptase (Invitrogen, Paisley,
UK) in a volume of 20 ml. The hot-start (Qiagen, Hilden,
Germany) RT-PCR was performed with 95uC for 15 min for one
cycle; then various amplification cycles for individual genes.
Human b-actin gene was amplified in parallel as an internal
control. The PCR primers are listed in Table 1. DNA relative
quantity was analysed using a gel program (version 3.0 computer
analyser of Media, Cybernetics, L.P, Silver Spring, MD) and
expressed as relative to the density of b-actin gene PCR product.
Electron Microscopy (EM)
Cells were fixed in 2.5% glutaraldehyde in 0.1 M phosphate
buffer, followed by secondary fixation in 1% osmium tetroxide in
0.1 M phosphate buffer. The specimen was dehydrated through
an ascending series of ethanols and embedded in TAAB epoxy
resin (TAAB, Reading, UK). Sections, 80 nm thick, were cut on a
Leica Ultracut E ultramicrotome (Leica, Milton Keynes, UK),
stained with Uranyl acetate and lead citrate and examined by
electron microscopy (Hitachi H7600, Berks, UK). For gold
labelling experiments, staining with Uranyl acetate and lead
citrate was omitted. The sections were incubated with monoclonal
antibody against insulin (K36aC10 at 1:100, Sigma, Dorset, UK)
at 4uC overnight. After 3 washes with PBS, the sections were
incubated with goat anti-mouse IgG (been pre-absorbed with
human tissues) conjugated with 10 nm gold particle
(EM.GMHL10, British Biocell, Cardiff, UK) and examined by
electron microscopy (Hitachi H7600, Berks, UK). The negative
control was performed in parallel with non-related IgG1
monoclonal antibody (replacing insulin antibody).
Immunochemical/immunohistochemical staining
The methods have been described previously [25,27]. Briefly,
cultured cells ortissues were mounted withOCTcompound (Merck
ltd, Nottingham, UK) and cryosectioned at 5 mm intervals. The
sections were incubated with antigen specific antibodies followed by
fluorescence conjugated 2
nd antibodies and visualised under
fluorescent or confocal microscopy. Two types of negative control
were performed: one was by replacing the primary antibody with
non-related subtype monoclonal antibodies or species related
normal serum; the other was by staining the non-transplanted
tissue sections with antigen specific antibodies. At least 3,000 cells
per count and 3 counts per sample were performed.
Animals and Surgical Procedures
Male SCID mice (20–25 g, C.B-17/Icr), purchased from Charles
River UK Ltd, were selected as recipients for the manipulated
hMSCs. The mice were maintained in filter-cages in the Compar-
ative Biology Centre at King’s College London, according to Home
Office (UK) guidelines for Animal Scientific Procedures. Diabetes
was induced by a single injection of STZ (180 mg/kg i.p) and
confirmed by the presence of hyperglycaemia. The diabetic condition
was allowed to stabilize for 3–10 days before transplantation. The
diabetic mice were randomly allocated into transplant recipient and
sham operated control groups. The transplantation procedures have
been described previously [25,27]. Briefly, under anaesthesia, a
median lateral laparotomy was performed and the left kidney was
exposed. Approximately 1,500 cell clusters (,3610
6 cells) in a
volume of 50 ml were transplanted into the kidney parenchyma by
direct insertion of a Hamilton syringe into the kidney at the lower
pole and the cells were discharged slowly into the parenchyma as the
syringe was slowly withdrawn. In the sham control group, a cell-free
saline injection was made in precisely similar fashion. Plasma glucose
was measured using a G2 blood glucose sensor from MediSense
(Abbott Laboratories, Abingdon, UK).
Intra-peritoneal glucose tolerance test (IPGTT)
After the mice had been fasted over-night the basal plasma
glucose level was determined. Glucose solution at 1.5 g/kg body
weight was injected intraperitoneally and plasma glucose levels
were determined at 30, 60, 90, 120 and 180 min post injection.
At the end of the experiments, blood, kidneys and pancreases
were retrieved. Immunohistochemistry was performed to deter-
mine the phenotype of grafted cells and cell nuclei were
counterstained with propidium iodide (Sigma, Dorset, UK) and
analysed by fluorescent or confocal microscopy. Hormone-positive
cells and the total transplanted cells (1500 graft cells per staining)
were counted under fluorescence microscope and the percentage
of positive cells was determined. The concentrations of human
specific insulin and C-peptide were determined by immunora-
dioassay (DSL, Texas, USA). Organs from sham mice were
studied in parallel as negative controls.
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(clone K36aC10) and glucagon (clone K79bB10) were purchased
from Sigma (Sigma, Dorset, UK). Rabbit anti human Ki67
antibodies were purchased from DAKO (DAKO, Glostrup,
Denmark). Rabbit anti human somatostatin antibodies and PYY
antibodies were from AbD Serotec (AbD Serotec, Oxford, UK).
Goat polyclonal antibody to Pdx-1: (sc-14664), monoclonal
antibody to NeuroD1: (sc-46684) and rabbit polyclonal
antibodies to Neurogenin 3 (sc-25654) were purchased from
Santa Cruz (Santa Cruz Biotechnology, CA, USA).
Statistics
All data are expressed as mean+/2 standard deviation. P,0.05
was considered as statistical different between groups, determined
by ANOVAR.
Results
The cell renewal capacity and the expression of markers
of both stem cell and pancreatic endocrine cells
Both cell lines (220R and 240L) showed the similar renewal
capacity in monolayer culture (Fig. S1a). The doubling times were
approximately 30 hrs, which did not change up to 10 cell passages
(Fig. S1b). The cell number increased by approximately 15-folds
per cell passage.
Both hMSC lines expressed the typical stem cell markers:
CD34, Oct4, Sox2 and Nanog [28–34] (Fig. 1a) and pancreatic
endocrine cell markers Pdx-1, NeuroD1, Ngn3 and Nkx6.1 [35–
38] (Fig. 1b). Two additional hMSC primary cells generated from
healthy donors in our institution, one from bone marrow and the
other from peripheral blood, also expressed markers of endocrine
Table 1. Primer sets for cloning, PCR and sequence analyses.
Genes Primer sets Product length
Pdx-1 F1(Clone) 59CGGGCCGCAGCCATGAACG39 874 bp
Pdx-1 R1(clone) 59CTCCTGCCTCTCATCGTGGTTCCTG39
Pdx-1 F2(PCR) 59CCGCCGCCGCACCCGTTCC39 508 bp
Pdx-1 R2(PCR) 59CGACCCCGCCACCCCCGACAG39
Pdx-1 Seq. F 59CAAAACCGCCGCATGAAGTGGA39
Pdx-1 Seq. R 59AGCTGAGCCGGGAGGTGGTGGTGA39
NeuroD1 F1 (Clone) 59AAATGAATTCATGACCAAATCGTACAGCGAGA39 1093 bp
NeuroD1 R1 (Clone) 59TCGCGTCGACCTAATCATGAAATATGGCATTGAGCTG39
NeuroD1 F2 (PCR) 59ATGAACGCAGAGGAGGACTCACTG39 410 bp
NeuroD1 R2 (PCR) 59TTGGTGGTGGGTTGGGATAAGC39
Ngn3 F 59GCGCCGGTAGAAAGGATGACGCC39 677 bp
Ngn3 R (Clone and PCR) 59CCCGGCTCCCTCCCTCTCCCTTAC39
INS F 59CATCAAGCACATTGTCC39 435 bp
INS R 59CTGGTTCAAGGGCTTTATTC39
INS F (internal/PCR) 5 TCTACCTAGTGTGCGGGGAACGAG 39 256 bp
INS R (internal/PCR) 59CAGGAGGCGGCGGGTGTGG 39
Glucagon F 59GCATTTACTTTGTGGCTGGGTC39 420 bp
Glucagon R 59AGTGATTTTGGTCTGAATC39
Somatostatin F 59 GGCGCCGAGATGCTGTCCTG39 314 bp
Somatostatin R 59 TGCGTTCTCGGGGTGCCATAG39
Pancreatic polypeptide Y F 59 CCACCTGCGTGGCTCTGTTACTAC39 292 bp
Pancreatic polypeptide Y R 59 CTGGGCTGGCGCTGCTCATGG39
GluT2 F 59GTTTTGGGTGGTCCACTGGATG39 523 bp
GluT2 R 59GCCACAGATCATAATTGCCCAAG39
GLK F 59GCCCCACAGCTCAACACAACCAG39 597 bp
GLK R 59CTCCCACCTTCACCAGCATCACC39
SUR1 F 59CCGGGACGACAAGAGGACAGTGGT39 401 bp
SUR1 R 59GGATGCCGGCGGAGGACAGGTA39
Kir6.2 F 59GGGGGCGCATGGTGACTGAG39 506 bp
Kir6.2 R 59GGTGCGGGCCTGGGTGGTGAT39
PC1/3 F 59 GTCCTCTTTTGCGCT TGGTGTGC 39 441 bp
PC1/3 R 59 TCCTTTGCCCGTAATGCCTTTTTG 39
Actin F 59CCCAGATCATGTTTGAGACC39 664 bp
Actin R 59CCAACAGGAGTACTTGCGCTCAG39
doi:10.1371/journal.pone.0002666.t001
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properties represent a robust and reproducible hMSC phenotype.
These cells were not analysed further.
On conversion to cluster culture (Fig. S1c), a condition favouring
differentiation into the beta cell phenotype [27], the expression of
CD34, Oct4, Sox2 and Nanog was greatly reduced (Fig. 1a).
Unexpectedly, the expression of Pdx-1, NeuroD1, Ngn3 and Nkx6.1
was also reduced (Fig. 1b). The expression of Pdx-1, NeuroD1 and
Ngn3 proteins was not detectable in the cluster cells by immunocy-
tochemical staining (data not shown). The expression of markers of
stem cells became undetectable in the implanted cells (Fig. S1d).
Human MSCs secreted insulin in vitro, but it was not
glucose regulated
Non-transfected hMSC (220R and 240L) lines were cultured in
clusters in the presence of the differentiation inducers (ABNG) for
6 days. No insulin mRNA was detected in vitro by RT-PCR.
Transplantation of these cells (3610
6 cells/mouse) into the kidney
parenchyma of mice rendered diabetic by streptozotocin (STZ)
treatment was associated with a short-lived small reduction in
mouse plasma glucose (19.47+/20.57 mM to 17.45+/20.77 mM
at day 7 post-transplantation p,0.01 n=8) (Fig. 1d). Sham
operated mice showed no change. The difference in plasma
glucose levels between the two groups of mice at day 7 post-
transplantation was significant (p,0.01), suggesting that the
hMSCs might produce insulin in vivo, although this could not be
confirmed by immunohistochemistry.
One possible reason for the failure of the hMSCs to differentiate
into a functional phenotype of beta cell is that the expression levels
of Pdx-1, NeuroD1 and Ngn3 were too low. Human MSCs were
transfected with a combination of Pdx-1, NeuroD1 and Ngn3 in a
ratio of 1:3:1 in weight without subsequent selection and the
Figure 1. Characteristics of human marrow stromal cells (hMSCs). Panel 1a and 1b show the typical gel analyses of hMSCs (220R and 240L) in
term of expression of makers for stem cells (1a) and pancreatic endocrine cells (1b); Lane M is the molecular weight, lane F, freshly isolated human
islets, lane hMSC C is the hMSC in cluster culture and lane hMSC M is the hMSC in monolayer culture. Panel 1c shows the similarity in the expression
of pancreatic endocrine cell marks among local generated primary human stromal cells and the 2 hMSCs lines: 220R and 240L. Lane BM is the primary
stromal cells derived from bone marrow and Lane p blood is the primary stromal cells derived from peripheral blood. Panel 1d shows the potential of
hMSCs to improve hyperglycaemia in the diabetic SCID mice. All experiments were repeated at least 3 times.
doi:10.1371/journal.pone.0002666.g001
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was aprox. 30% as assessed by counting the green fluorescent
protein (GFP) positive cells under the fluorescent microscope
against total cell number (Fig. S2a). Analyses of GFP expressing
cells by fluorescence-activated cell sorter analysis, the transfection
efficiency was .85% (Fig. S2b, S2c). The difference was possibly
due to the different detection sensitivities in the two methods. The
ratio of expression of the three genes in the transfected hMSCs was
closed to 1:3:1 as assessed by RT-PCR as expected (Fig. S2d). The
expression of the three genes was observed in majority of the cells
48 hr post transfection, as assessed by immunocytochemical
staining. The 3 proteins were major located in nuclei, but some
of them also presented in cytoplasm (Fig. 2a). For differentiation
induction, cells were converted into clusters 48 hrs post-transfec-
tion, and incubated with differentiation reagents for 6 days. The
hMSC/PNNs began to express low-level preproinsulin mRNA
(Fig. 2b) and cellular insulin protein (156.25621.17 mU/
3610
6 cells) while non-transfected control cells did not
(13.0864.28 mU/3610
6 cells, p,0.01, Fig. 2c). The medium of
the differentiated induced hMSC/PNNs at day 6 contained insulin
(220645.2 mU/3610
6 cells), which was not observed in the
nontransfected hMSCs. To prove the true expression of insulin
gene in vitro, the PCR DNA fragment corresponding with the
expected size was cut out of the agarose gel following
electrophoresis, purified and partially sequenced. The DNA
sequence was matched to the authentic insulin DNA gene
(NM_000207, data not shown). In addition, the purified DNA
was used as a template to amplify the insulin gene using an internal
insulin PCR primer set (Table 1) and the expected size of 256 bp
PCR product was observed (data not shown). Intact hMSC/PNN
cells secreted insulin (245650.29 mU/3610
6 cells) at 20 mM
glucose, ,10-fold more than non-transfected hMSCs
(24.6566.21 mU/3610
6 cells, p,0.01). However, insulin secre-
tion was not significantly different in hMSC/PNNs when glucose
concentration was reduced to 2 mM (Fig. 2d). The expression of
SUR1 and Kir6.2, a K
+-ATP channel required for the regulation
of insulin secretion, was not detectable in hMSC/PNNs in vitro
(data not shown). Although immunocytochemical staining for
insulin in the hMSC/PNNs for light microscopy did not provide
conclusive evidences (data not shown), electron microscopy
analyses did confirm the presence of insulin secretory granule-
like structures in the hMSC/PNNs (Fig. 2e). The hMSC/PNNs
picked up immuno-gold particles (Fig. 2f), as did the secretory
granules of freshly isolated human islet cells (Fig. 2g). No gold
particles were observed in the negative control staining, in which
the hMSC/PNNs were stained with non-related IgG1 monoclonal
antibody (Fig. 2h). The number of gold particles per granule was
limited, probably as a result of the fixation process used (2.5%
glutaraldehyde), which was selected to preserve granule ultra-
structure but might impair the antigenicity of the insulin present.
Human MSC/PNNs matured further in vivo
To examine whether hMSC/PNNs would mature into glucose-
responsive insulin-producing cells in vivo, hMSC/PNNs
(3610
6 cell/mouse) were differentiation induced and then trans-
planted into the parenchyma of the left kidney in male SCID
diabetic mice, using non-transfected hMSC cells as a control, which
were differentiation induced in the same manner as for hMSC/
PNNs. Mice transplantation with hMSC/PNNs was associated with
a slow decline of initial hyperglycaemia (from 18.9+/20.75 to
7.63+/21.63 mM, p,0.01, n=16). In 13 of the 16 mice, plasma
glucose reached to normal ranges (6.9+/20.64 mM) within 4
weeks, with normoglycaemia sustained for a further 2 weeks, at
which time the animals were sacrificed (Fig. 3a). Immunohisto-
Figure 2. Human MSCs expressed insulin in vitro following
differentiation induction. Panel 2a shows the expression of Pdx-1,
NeuroD1 and Ngn3 in hMSCs 48 hr post transfection with the 3 genes.
Majority of the gene product (green fluorescence) was located in nuclei,
but some cells with cytoplasmic expression in all the 3 genes. Panel 2b
shows the mRNA of preproinsulin in hMSC/PNNs following 6 days’
differentiation induction in vitro, assessed by RT-PCR. The lanes 1–4
show the typical 4 different RT-PCR experiments on the expression of
insulin in hMSC/PNNs, lane 3M shows the expression of insulin in
human islet cells after 3 week in monolayer culture. Panel 2c shows the
presence of insulin protein content in hMSC/PNNs following differen-
tiation induction following correction with protein concentration. Panel
2d shows the insulin secretion by hMSCs and hMSC/PNNs following
glucose challenge in a static incubation assay. Panel 2e shows the
presence of insulin secretory granules in the hMSC/PNNs in a typical
electronic microscopy picture and the magnification indicator is 2
microns. The typical insulin secretory granules are arrowed. Panel 2f
shows the presence of insulin protein in hMSC/PNNs, as assessed by
immunogold labelling experiments. Panel 2g shows the insulin protein
in human islets, served as positive control of 2f, while 2h is the negative
control of 2f, in which hMSC/PNNs were stained with non-insulin
related IgG1 antibody. The black dots are the gold particles that
labelled insulin protein. The magnification indicators in panel 2f–2h are
500 nm. All experiments were repeated at least 3 times.
doi:10.1371/journal.pone.0002666.g002
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presence of insulin positive cells (12.562.6%, Fig. 3b, n=10) and
glucagon-expressing cells (6.4361.94%, Fig. 3c, n=10) among the
grafted cells, while the negative controls on the consecutive sections
did not show any positive staining, neither there were positive
staining on non-transplanted kidney sections with the same anti-
insulin antibody (Fig. S3). No somatostatin or pancreatic polypep-
tide-expressing cells were detected. Recipients of hMSC/PNNs
responded positively to an intraperitoneum glucose tolerance test
(IPGTT) by significantly lower plasma glucose within a 3 hr test
period, although the hMSC/PNNs mice were less efficient than
mice transplanted with fresh human islets (800 islet IEQ/mouse)
(Fig.3d).ThemeanofhumanspecificC-peptidelevelswereapprox.
1.5 ng/ml, a 3–fold higher in blood of the hMSC/PNN recipients
after IPGTT than in non-IPGTT tested mice (Fig. 3e, p,0.01,
n=6).Thepancreasesfromthe hMSC/PNN miceshowed only few
individual insulin positive cells (Fig. 3f and Fig. S4).
RNA extracted from the hMSC/PNNs bearing kidneys showed
the presence of insulin mRNA as an unique single band (Fig. 3g),
which was dramatically different from the multiple banding pattern
observed in the pre-transplant hMSC/PNNs (Fig. 2b), suggesting
that the insulin-producing cells had undergone a phase of
maturation and differentiation. The hMSC/PNNs engrafted
kidneys also expressed glucagon and somatostatin mRNA (Fig. 3g),
although somatostatin protein was not detectable in the grafts,
confirming that the cells not only differentiated into beta cells but
also into alpha cells and possibly somatostatin-producing cells as
well. The hMSC/PNNs engrafted kidneys contained mRNAs for
GluT-2 and Kir6.2 (Fig. 3g), key genes in beta cells for glucose
intake and insulin secretion regulation. However, the expression of
SUR1 gene was undetectable by RT-PCR (Fig. 3g). Control grafted
kidneys from mice transplanted with non-transfected hMSCs cells
did not show these changes (Fig. 3g). In addition, human MSCs
express prohormone convertase 1/3 (NM_000439, PC1/3) (Fig. 3h
lane 2) and the expression was enhanced when the cells were
clustered and reached to similar expression level with fresh human
islets when the cells were transfected with Pdx-1, NeuroD1 and
Ngn3 and with differentiation induction (Fig. 3h lane 4), suggesting
that these cells might be able to process proinsulin to mature insulin.
The 3-gene transfection seemed to enhance the expression of PC1/
3 in hMSC/PNNs as the different expression was observed in lanes
between 3 and 5, 6 and 7 (Fig. 3h). Mouse kidney does not express
the human version of the PC1/3 (Fig. 3h lane 5).
Human MSCs did not form teratoma structure in the
transplant recipients
The potential risk of hMSCs to form teratoma in transplanted
mice was ascertained by assessing the presence of proliferation
marker Ki67 protein [39], in monolayer culture (Fig. 4a), in cluster
culture in the presence of differentiation inducers ABNG (Fig. 4b)
and in the mouse kidney sections containing the grafts of hMSC
(in clusters). A mean of 10.7962.14% in Ki67
+ve hMSCs after 5-
days in monolayer culture was observed, which fell to
Figure 3. Effect of hMSC/PNNs on plasma glucose in diabetic
mice. Panel 3a shows plasma glucose concentrations over days in
transplanted mice. The symbol of blue diamond represents mice
transplanted with hMSC/PNN (n=16); The yellow triangle represents
mice transplanted with hMSC with a phase of differentiation (n=12)
and the pink square represent the sham control (n=12). Panel 3b and
3c show the presence of insulin and glucagon positive cells (green
fluorescence) in the human MSC/PNNs transplanted grafts in typical
mouse kidney sections respectively. In panel 3b, two insulin- expressing
clusters were taken at higher power and shown in inset. Panel 3d shows
the response of transplanted mice to a glucose challenge. The symbol
of blue diamond represents mice transplanted with hMSC/PNN (n=6);
The pink square represents mice transplanted with the non-transfected
hMSCs with a same phase of differentiation (n=6) and symbol of yellow
triangle represents mice transplanted with human islets (800 IEQ/
mouse, n=6). Panel 3e shows the differences in human specific C-
peptide in mice after the glucose tolerant test (IPGTT) and without
IPGTT. Panel 3f shows the typical residuals of the remaining insulin
positive cells (green fluorescence) in the mouse panaceas of hMSC/
PNNs recipients. Please note that the images is presented at low power
to give a broad view of the tissue section, emphasizing the
disappearing of islet cells from the STZ treated pancreases. Panel 3g
shows the presences of mRNA of insulin, glucagons, somatostatin, GluT-
2 and Kir6.2, but lacks of human SUR1 gene, in the kidneys transplanted
with hMSC/PNN cells, using mouse kidneys transplanted with human
islet cells as positive control, and mouse kidneys transplanted with
hMSC cells as negative control. Panel 3h shows the expression of
prohormone convertase 1/3 in hMSC/PNN cells, illustrating the effect of
the 3 transpected genes on the expression of prohormone convertase
1/3. The sequences of the lanes are: MW–DNA molecular weight marker,
1–fresh human islet cells, 2–hMSC in monolayer, 3–hMSC in cluster
culture, 4–hMSC/PNN cells with differentiation induction, 5–mouse
kidney, 6-mouse kidneys transplanted with hMSC cells with a phase of
differentiation induction and 7–mouse kidneys transplanted with
hMSC/PNN cells with differentiation induction. All experiments were
repeated .3 times.
doi:10.1371/journal.pone.0002666.g003
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inducers (Fig. 4c) and beyond detection in the implanted cells.
Neither Ki67+ve cells nor teratoma structures were observed in
the grafts 1–6 weeks post-transplantation, although it should be
noted that no study lasted .6 weeks post transplantation.
Discussion
This study explores the potential of human MSCs as a source
for glucose-regulated insulin-producing cells and also addresses
some of the safety issue of these cells for clinical use.
We developed a robust system to direct the differentiation of
hMSCs into insulin-producing cells through a transient, non-viral
genomic reprogramming approach. The half-life of the transfected
plasmid DNA was 8ds in cluster cells, while it was 3 days in
monolayer cells. This is possibly due to the near zero proliferation
activity in the clustered cells (Zhao and Huang, unpublished).
Although hMSC have previously been shown to express insulin at
mRNA level with the infection of recombinant Pdx-1 adenovirus
[5], only a small number of MSCs became insulin positive cells
when no gene modification had taken place [20–22]. A recent
study showed that genetically modulated hMSCs with recombi-
nant Pdx-1 adenovirus were able to reduce mouse blood glucose
with detectable human C-peptide (0.06–0.39 ng/ml) [23]. Our
approach using a non-virus triple gene transfection approach has
resulted in a much higher percentage of insulin expressing cells
(.12%). The mean human C-peptide in the non-glucose tolerant
test mice was ,0.5 ng/ml (n=6). In addition, there was
significant number of glucagon-expressing cells (.6%). The
majority of hMSC/PNNs transplanted mice (13/16) returned to
normoglycaemia. The presence of mRNAs for insulin, glucagon,
somatostatin, GluT-2 and Kir6.2 in the cells from the rescued
kidneys shows that the cells have developed into a phenotype of
pancreatic endocrine cells. The presence of insulin mRNA in the
graft bearing kidneys refutes the possibility that the insulin in the
insulin producing cells is derived from the deposition of circulating
insulin [40].
Human MSCs have a high renewal capacity and express a
typical panel of stem cells markers: CD34, Oct4, Sox2 and Nanog.
Cells from human pancreases were recently shown to contain cells
expressing these markers of stem cells [41]. The proliferation rate
for hMSCs was not changed up to 10 passages in both 220R and
240L hMSC lines (Fig. S1b). Potentially hMSCs could become
almost unlimited cell sources as the cells number increased ,15
folds per cell passage. For example, if we started with one million
cells, there would be .10
16 cells after 10 cell passages. The other
advantage in hMSCs is that the proliferation capacity reduces
dramatically following the differentiation induction phase and
ceases to proliferate following transplantation as no Ki67 protein
was detected from the grafts, which is different from the
embryonic stem cells that form teratoma in recipients [42]. More
interestingly the cells also express a panel of key genes required for
the development and maintenance of functional phenotypes of
pancreatic beta cells: Pdx-1, NeuroD1, Ngn3 and Nkx6.1. The
expression of Pdx-1, NeuroD1 and Ngn3 in hMSC was a novel
observation. Based on the assumption that MSCs could differen-
tiate into neurons because they have expressed key neuronal genes
[15], hMSCs may be taken to have innate potential to become
beta cells, since they express these key beta cell markers (Pdx-1,
NeuroD1 Ngn3, and Nkx6.1). These properties of hMSCs seem to
represent a robust and reproducible hMSCs phenotype, as the
expression of the same markers for stem cell and endocrine cells
was detected in two additional hMSC primary cells derived from
healthy donors in our own institution (Fig. 1e). Despite this
potential, intact hMSCs seemed unable to differentiate into
insulin-producing cells in vivo, in line with others’ observations
[43–45]. We believe that single Pdx-1 gene is not sufficient to
generate functional insulin-producing cells [25]. The rationale of
using Pdx-1, NeuroD1 and Ngn3 as genomic modulators is that
Pdx-1, NeuroD1 and Ngn3 genes are all required for the
development of beta cells, while Pdx-1 and NeuroD1 play
important roles in the maintenance for the functional phenotypes
of beta cells. As hMSCs are not embryonic cells, we are not trying
to mimic the patterns in the beta cell development. We simply
hypothesised that the combination of these three genes would
work synergistically to make hMSCs respond to the cocktail of
differentiation inducers and to initiate the differentiation in vitro.
We also hypothesised that the in vitro induced cells would
differentiate further into glucose responsive insulin producing cells
under the hyperglycaemia with right supporting environments in
the SCID mice, based on our previous observation [25,27]. It has
been shown that Ngn3 can initiate the differentiation of cells
toward endocrine cells by modulating the E-box in the promoter
of NeuroD1 gene [46]. There were reports that Pdx-1 works better
together with Ngn3 or NeuoD1 to enhance the insulin expression
[47]. Indeed the combination of Pdx-1, NeuroD1 and Ngn3
achieved more insulin-producing cells than the combination of
Pdx-1, NeuoD1 and Isl1 (data not shown). The gene ratio was
Figure 4. Analyses of the proliferation potential in hMSCs. Panel 4a shows the hMSC cells in monolayer culture, while the cluster cultured
cells are shown in panel 4b. Panel 4c summarised the Ki67positive cells in both monolayer and cluster cultures. The yellow dots (the merged colour of
green fluorescence and red propidium iodide) represent the Ki67positive cells. Some of the Ki67 positive cells are indicated with arrowhead. All
experiments were repeated .3 times.
doi:10.1371/journal.pone.0002666.g004
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freshly isolated human islets and was established as the best
combination following a serial of tests.
At least in vitro, the amount of insulin content and in secretion
was fairly small, estimated as 1/1000–1/500 respectively of freshly
isolated human islets. The insulin secretion was not glucose
regulated as components of K
+-ATP channel was not detected.
Insulin was synthesized and secreted at the same time. This may
explain why relatively lower insulin content (156 mU/3610
6 cells)
than insulin secreted into the differentiation induction medium
(220645.2 mU/3610
6 cells). The cells may not establish a storage
capacity for the synthesized insulin in vitro. This phenomenon is
similar to those described for persistent hyperinsulinaemic
hypoglycaemia of infancy (PHHI) cells. In PHHI cells the K
+-
ATP channel is mutated and the insulin is secreted as it is
synthesized [48]. Nevertheless, our cells did differentiate further
following transplantation and developed an element of glucose-
responsive insulin secretion in vivo, as the plasma glucose level was
reduced in association with the elevated levels in both insulin and
C-peptide after a glucose challenge. These cells had high-level
expression of Kir6.2, which was not present in vitro. There was no
expression of SUR1 gene in vitro or in vivo. Whether the cells
developed an alternative mechanism to regulate insulin secretion
in these cells is not clear. Mice lack functional SUR1 protein
appeared only glucose tolerant impairment but not diabetes at
least in some period of their life [49], suggesting that beta cells may
be able to compensate the lost function of K-ATP channel. It may
be relevant that the insulin-producing cells were present in clusters
similar to those seen in grafts of human islet cells, and distinct from
our previous study in which insulin-producing cells were scattered,
through a single Pdx-1 gene transfection [25]. There is evidence
that beta cells function better in cluster structures [50], and
forming clusters may be integral to their nature. The cluster
formation suggests that the present triple gene transfection may be
superior to single Pdx-1 gene transfection.
How the cells developed into a functional phenotype in vivo is
not clear and is worthy of further exploration. This study provides
a model to modify hMSCs further for glucose-regulated-insulin-
producing cells for the clinical therapy of TIDM. It offers the
potential for generating new islet cells from patients’ own bone
marrow, although further manipulation is likely to be required to
achieve cells resistant to inflammatory damage and immunological
attack. The interpretation of this study for clinical use is limited as
hMSC lines were used rather than primary hMSC cells.
Supporting Information
Figure S1 Characterization of human MSC cells. Panel 1a and
1c show the morphologies of hMSCs in monolayer and in cluster
respectively. Panel 1b shows the proliferation capacities of cells at
passages between 2 and 10. Panel 1d shows the typical gel analyses
of hMSCs in term of expression of makers for stem cells before and
after the differentiation induction. Lanes 1, 3, 5,7 and 9 are the
hMSCs before the implantation and Lanes 2, 4, 6, 8 and 10 are
the hMSCs after the implantation.
Found at: doi:10.1371/journal.pone.0002666.s001 (0.30 MB TIF)
Figure S2 Assessment of the transfection of hMSC cells. Panel
2a shows the transfection efficiency in hMSC cells. The cells that
have been transfected with the pIRES2-EGFP plasmid (BD
Bioscience Clontech, Oxford UK) show the expression of green
fluorescence protein (GFP). The transfection was performed with
pIRES2-EGFP plasmid using lipofectamine 2000 reagents (In-
vitrogen, Paisley, UK). Approx. 3063.56% cells were positive for
GFP by manual cell counting. Panel 2b and 2c show the GFP
positive hMSC cells assessed by fluorescence-activated cell sorter
analysis according to method published previously [51]. Over 85%
cells were shown positive for GFP (2b) against the negative control
(2c), transfected with non-GFP plasmid. Panel d shows the typical
PCR analyses of the expression of Pdx-1, NeuroD1 and Ngn3 Pre-
and 72 hr post-transfection with the three genes.
Found at: doi:10.1371/journal.pone.0002666.s002 (0.39 MB TIF)
Figure S3 Assessment of the specificity of anti human insulin
antibody. Non-transplanted SCID mouse kidney cryosections
were used to assess the specificity of anti human insulin
monoclonal antibody (K36aC10, Sigma, Dorset, UK) in parallel
with hMSC/PNN transplanted mouse kidney sections. The typical
fluorescent microscopy image shows that there is no specific
binding of this antibody to normal SCID mouse kidney tissues
under the titration used in this study.
Found at: doi:10.1371/journal.pone.0002666.s003 (2.54 MB TIF)
Figure S4 Assessment the insulin expressing cells in mouse
pancreases following streptozotocin treatment. Mouse pancreases
retrieved from the hMSC/PNN-transplanted mice were cryosec-
tioned and stained for insulin (green). The cell nuclei were
counterstained with propidium iodide (red). The images were
taken at low power to emphasize that only very few insulin-
expressing cells were present in the moue pancreases. No intact
islets were observed in the mouse pancreases.
Found at: doi:10.1371/journal.pone.0002666.s004 (1.86 MB TIF)
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